Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer

Kim et al. isolated preneoplastic neuroendocrine cells from a mouse model of small cell lung cancer (SCLC) and found that ectopic expression of L-Myc conferred tumor-forming capacity. An RNA polymerase I inhibitor used to target rRNA synthesis resulted in significant tumor inhibition in an autochthonous Rb/p53-deleted mouse SCLC model.

• Publication year

  2016

• Venue

  Genes & Development

• Publication date

  2016-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1101/gad.279307.116PMID 27298335PMCID 4911928
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.

  2016cited by this paper
• The Interaction of Myc with Miz1 Defines Medulloblastoma Subgroup Identity.

  2016cited by this paper
• Targeting the translation machinery in cancer

  2015cited by this paper
• The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung

  2015cited by this paper
• Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis.

  2015cited by this paper
• Comprehensive genomic profiles of small cell lung cancer

  2015cited by this paper
• Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

  2015cited by this paper
• Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing.

  2014cited by this paper
• PTEN Is a Potent Suppressor of Small Cell Lung Cancer

  2014cited by this paper
• L-Myc expression by dendritic cells is required for optimal T-cell priming

  2014cited by this paper
• MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.

  2014cited by this paper
• Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells

  2014cited by this paper
• MYC on the path to cancer.

  2012cited by this paper
• Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

  2012cited by this paper
• Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

  2012cited by this paper
• Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung.

  2011cited by this paper
• Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.

  2011influential reference
• MYC as a regulator of ribosome biogenesis and protein synthesis

  2010cited by this paper
• Promotion of direct reprogramming by transformation-deficient Myc

  2010cited by this paper
• Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.

  2010cited by this paper
• Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

  2010cited by this paper
• Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase

  2009cited by this paper
• Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency

  2008cited by this paper
• c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I

  2005cited by this paper
• c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription

  2005cited by this paper
• dMyc transforms cells into super-competitors.

  2004cited by this paper
• Drosophila myc regulates organ size by inducing cell competition.

  2004cited by this paper
• Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model.

  2003cited by this paper
• Expression and activity of L-Myc in normal mouse development

  1996cited by this paper
• Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells

  1992influential reference
• L-myc cooperates with ras to transform primary rat embryo fibroblasts

  1988influential reference
• myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course.

  1987cited by this paper
• L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer

  1985cited by this paper

• Metastatic small cell lung cancer arises from TP53/RB1-deficient and MYC overproduction hESC-derived PNECs

  2025cites this paper
• A MYC Family Switch: L-MYC Drives and Maintains Neuroendocrine Lineage Programs in Prostate Cancer

  2025cites this paper
• SMARCA4 loss promotes late-stage tumor progression in non-neuroendocrine small-cell lung cancer.

  2025cites this paper
• Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer

  2025cites this paper
• SMARCA4 is essential for early-stage tumor development but its loss promotes late-stage cancer progression in small-cell lung cancer

  2025influential citation
• Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors.

  2025cites this paper
• Asparagine synthetase (ASNS) Drives Tumorigenicity in Small Cell Lung Cancer

  2025cites this paper
• Recent Research on Role of p53 Family in Small-Cell Lung Cancer

  2025cites this paper
• The natural alkaloid nitidine chloride targets RNA polymerase I to inhibit ribosome biogenesis and repress cancer cell growth

  2025cites this paper
• Tumor Heterogeneity and Plasticity in Small Cell Lung Cancer

  2025cites this paper
• Acquired Cross-resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC paralogs.

  2024cites this paper
• Genetically-engineered mouse models of small cell lung cancer: the next generation

  2024cites this paper
• Genetic Alterations in Lung Cancer

  2024cites this paper
• Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targets

  2024cites this paper
• CX-5461 Preferentially Induces Top2α-Dependent DNA Breaks at Ribosomal DNA Loci

  2024cites this paper
• Landscape and Treatment Options of Shapeshifting Small Cell Lung Cancer

  2024cites this paper
• Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer.

  2024cites this paper
• Alcohol Exposure Induces Nucleolar Stress and Apoptosis in Mouse Neural Stem Cells and Late-Term Fetal Brain

  2024cites this paper
• P53 and Rb Aberrations in Small Cell Lung Cancer (SCLC): From Molecular Mechanisms to Therapeutic Modulation

  2024cites this paper
• Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer.

  2024cites this paper
• Current Knowledge of Small Cell Lung Cancer Transformation from Non-Small Cell Lung Cancer.

  2023cites this paper
• Actin Dysregulation Induces Neuroendocrine Plasticity and Immune Evasion: A Vulnerability of Small Cell Lung Cancer

  2023cites this paper
• Identification of potential common genetic modifiers of neurofibromas: a genome wide association study in 1,333 neurofibromatosis type 1 patients.

  2023cites this paper
• FORMATION OF MALIGNANT, METASTATIC SMALL CELL LUNG CANCERS THROUGH OVERPRODUCTION OF cMYC PROTEIN IN TP53 AND RB1 DEPLETED PULMONARY NEUROENDOCRINE CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS

  2023cites this paper
• Acquired Cross-resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC paralogs

  2023cites this paper
• A Synthetic Lethal Approach to Drug Targeting of G-Quadruplexes Based on CX-5461.

  2023cites this paper
• Single-Cell Evolutionary Analysis Reveals Drivers of Plasticity and Mediators of Chemoresistance in Small Cell Lung Cancer.

  2023cites this paper
• Circlehunter: a tool to identify extrachromosomal circular DNA from ATAC-Seq data

  2023cites this paper
• The New Way to Define Key Oncogenic Drivers of Small Cell Lung Cancer

  2023cites this paper
• CRACD, a gatekeeper restricting proliferation, heterogeneity, 1 and immune evasion of small cell lung cancer 2

  2023cites this paper
• Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes.

  2023cites this paper
• A Review on Small-Cell Lung Cancer: Epidemiology, Pathophysiology, Risk Factors, Diagnosis, Clinical Management and Treatment Modalities

  2023cites this paper
• A multiplexed in vivo approach to identify driver genes in small cell lung cancer

  2022cites this paper
• Effect of chromatin modifiers on the plasticity and immunogenicity of small-cell lung cancer

  2022cites this paper
• Regulation of RNA Polymerase I Stability and Function

  2022cites this paper
• Single Cell lineage Tracing Identifies Cancer Testis Antigens as Mediators of Chemoresistance in Small Cell Lung Cancer

  2022cites this paper
• WNT5A-RHOA signaling is a driver of tumorigenesis and represents a therapeutically actionable vulnerability in small cell lung cancer.

  2022cites this paper
• Ribosome-Directed Therapies in Cancer

  2022cites this paper
• Inhibition of karyopherin β1-mediated nuclear import disrupts oncogenic lineage- defining transcription factor activity in small cell lung cancer.

  2022cites this paper
• Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer

  2022cites this paper
• A conserved YAP/Notch/REST network controls the neuroendocrine cell fate in the lungs

  2022cites this paper
• WNT5A-RHOA axis is a new vulnerability in small-cell lung cancer

  2022cites this paper
• KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer

  2022cites this paper
• MYCL-mediated reprogramming expands pancreatic insulin-producing cells

  2022cites this paper
• Sox2 Is an Oncogenic Driver of Small-Cell Lung Cancer and Promotes the Classic Neuroendocrine Subtype

  2021cites this paper
• HERC2 inactivation abrogates nucleolar localization of RecQ helicases BLM and WRN

  2021cites this paper
• Small-cell lung cancer

  2021cites this paper
• Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer

  2021cites this paper
• Distinct Signatures of Genomic Copy Number Variants Define Subgroups of Merkel Cell Carcinoma Tumors

  2021cites this paper
• Stem cells and lung cancer

  2021cites this paper
• Protein neddylation as a therapeutic target in pulmonary and extrapulmonary small cell carcinomas

  2021influential citation
• Unique role and vulnerability of EP300 KIX domain in small-cell lung cancer

  2021cites this paper
• Rlf-Mycl gene fusion drives tumorigenesis and metastasis in a mouse model of small cell lung cancer.

  2021cites this paper
• Down-Regulation of CXXC5 De-Represses MYCL1 to Promote Hepatic Stellate Cell Activation

  2021cites this paper
• Regulation of hematopoiesis and B-lymphocyte development by histone deubiquitinases

  2021cites this paper
• CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer

  2021cites this paper
• Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer

  2021cites this paper
• RLF‐MYCL fusion: A new tool for treatment of small cell lung cancer

  2021cites this paper
• HERC2 inactivation abrogates nucleolar localization of RecQ helicases BLM and WRN

  2021cites this paper
• Pre-clinical models of small cell lung cancer and the validation of therapeutic targets

  2020cites this paper
• MYC, MYCL, and MYCN as therapeutic targets in lung cancer

  2020cites this paper
• Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age

  2020cites this paper
• The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer

  2020cites this paper
• FGFR1 Is Critical for RBL2 Loss–Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer

  2020influential citation
• MYCN drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity

  2020cites this paper
• New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts

  2020cites this paper
• Advances in Small-Cell Lung Cancer (SCLC) Translational Research.

  2020cites this paper
• MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.

  2020cites this paper
• MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer.

  2020cites this paper
• Compensation between Wnt-driven tumorigenesis and cellular responses to ribosome biogenesis inhibition in the murine intestinal epithelium

  2020cites this paper
• Epigenetic Landscape of Small Cell Lung Cancer: Small Image of a Giant Recalcitrant Disease.

  2020cites this paper
• RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation

  2020cites this paper
• Compensation between Wnt-driven tumorigenesis and cellular responses to ribosome biogenesis inhibition in the murine intestinal epithelium

  2020cites this paper
• MYC and the unfolded protein response in cancer: synthetic lethal partners in crime?

  2020cites this paper
• New insights into small‐cell lung cancer development and therapy

  2020cites this paper
• Cooperation between ETS transcription factor ETV1 and histone demethylase JMJD1A in colorectal cancer

  2020cites this paper
• N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.

  2019cites this paper
• Oncogenic role of FGFR1 and vulnerability of RBL2-FGFR1 axis in small cell lung cancer development

  2019cites this paper
• Classic oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer

  2019cites this paper
• Recent progress in mapping the emerging landscape of the small-cell lung cancer genome

  2019cites this paper
• Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer

  2019cites this paper
• An Integrated Multi-Omics Approach to Identify Genetic Underpinnings of Heart Failure and its Echocardiographic Precursors: The Framingham Heart Study.

  2019cites this paper
• Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.

  2019cites this paper
• 1 N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer

  2019cites this paper
• MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion

  2019cites this paper
• Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin

  2019cites this paper
• Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition.

  2018influential citation
• Regulation of RNA Polymerase I Transcription in Development, Disease, and Aging.

  2018cites this paper
• Transcriptional deregulation underlying the pathogenesis of small cell lung cancer.

  2018influential citation
• NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.

  2018cites this paper
• Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models.

  2018cites this paper
• The Expanding World of N-MYC-Driven Tumors.

  2018influential citation
• ROLE OF P300 ZZ DOMAIN IN CHROMATIN ASSOCIATION AND HISTONE ACETYLATION

  2018cites this paper
• Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells

  2018cites this paper
• New roles for Dicer in the nucleolus and its relevance to cancer

  2017cites this paper
• Inhibition of post-transcriptional steps in ribosome biogenesis confers cytoprotection against chemotherapeutic agents in a p53-dependent manner

  2017cites this paper
• Biology and evolution of poorly differentiated neuroendocrine tumors

  2017cites this paper
• Therapeutic Approaches Targeting MYC-Driven Prostate Cancer

  2017cites this paper
• Family matters: How MYC family oncogenes impact small cell lung cancer

  2017cites this paper
• Small-cell lung cancer: what we know, what we need to know and the path forward

  2017cites this paper